Swiss-based Galderma, a joint venture between Nestle and L'Oreal, today said it is aiming at around five-fold growth in sales to Rs 500 crore by 2018 in its dermatology business in India, on the back of new product launches and aggressive marketing.
The company, which produces and sells a wide range of skin health related products, said sales is expected to touch Rs 100 crore by the end of this year, Galderma India Managing Director G Sathya Narayanan told PTI.
"There is a huge potential in India for our products. People are now getting conscious about their skin. India is a huge market for dermatology," Narayanan said.
More From This Section
Apart from big metros, there is a huge potential in tier-II and tier-III cities. Purchasing power of people is also increasing, he added.
The company has planned aggressive marketing strategy through which it plans to make its products reach all major cities of the country in the next two years.
To increase awareness about products, the company is also planning consumer awareness programmes in different parts of the country, said Madhusudhan H K, Head of Galderma India's Aesthetic and Corrective Dermatology Business.
"We are also launching training programmes for doctors as these products require special skills to inject in body, mainly faces. By end of this year, the company is opening 'Galderma Academy' in Mumbai to impart skills in doctors," Madhusudhan added.
He said soon the company would launch 'Restylane Vital' in India. It helps in enhancing skin glow.
"Going forward we will be launching more products for body contouring, breast augmentation and hip augmentation," he said, adding the firm is planning to launch three-four new products in the country in the next six months.
Restylane Vital and Restylane Vital Light improves skin quality over time, Madhusudhan added.
He said that these products, when injected in the face, neck or hands, provide vital nourishment to the skin.
The company, which has manufacturing units in the US, France and Sweden, mainly imports its products and sells in India.